RayKnowChina Research Map
Shortlist

Taiyuan

Second Hospital of Shanxi Medical University

山西医科大学第二医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Hospital of Shanxi Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
  2. Osteosarcoma骨肉瘤16 papers led
  3. Multiple myeloma多发性骨髓瘤6 papers led
  4. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  5. Haemophilia A血友病 A6 papers led
  6. Fanconi anaemia范可尼贫血1 paper led
  7. IgG4-related diseaseIgG4相关性疾病4 papers led
  8. Takayasu arteritis大动脉炎1 paper led
  9. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  10. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  11. Fabry disease法布雷病0 papers led
  12. Behçet disease白塞病1 paper led
  13. IgA nephropathyIgA 肾病4 papers led
  14. Osteogenesis imperfecta成骨不全症0 papers led
  15. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Taiyuan for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 3320232024: 4420242025: 442025

5 hospitals in Taiyuan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led16
  1. GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.2025Neoplasia (New York, N.Y.)
  2. DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway.2025Scientific reports
  3. Genetically predicted plasma metabolites mediate the causal relationship between gut microbiota and osteosarcoma.2025Scientific reports
  4. Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis.2025The FEBS journal
  5. Characterization of the gut microbiota and fecal metabolome in the osteosarcoma mouse model.2024Aging
  6. Cisplatin and doxorubicin chemotherapy alters gut microbiota in a murine osteosarcoma model.2024Aging
  7. KNTC1 knockdown inhibits the proliferation and migration of osteosarcoma cells by MCM2.2024Molecular carcinogenesis
  8. PRG4 represses the genesis and metastasis of osteosarcoma by inhibiting PDL1 expression.2024Tissue & cell
  9. Natural Chlorogenic Acid Planted Nanohybrids with Steerable Hyperthermia for Osteosarcoma Suppression and Bone Regeneration.2023Advanced healthcare materials
  10. Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression.2023BMC medical genomics
  11. 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis.2023Molecular medicine (Cambridge, Mass.)
  12. Transcriptomics and metabolomics reveal changes in the regulatory mechanisms of osteosarcoma under different culture methods in vitro.2022BMC medical genomics
  13. Necdin, one of the important pathway proteins in the regulation of osteosarcoma progression by microRNA-200c.2022Bioengineered
  14. A bone implant with NIR-responsiveness for eliminating osteosarcoma cells and promoting osteogenic differentiation of BMSCs.2022Colloids and surfaces. B, Biointerfaces
  15. Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma.2021Bioengineered
  16. VEGF-C/VEGFR-3/iNOS Signaling in Osteosarcoma MG63 Cells Mediates Stimulatory Effects on Human Umbilical Vein Endothelial Cell Proliferation.2021Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
Earlier papers (2016–2020)3
  1. Long noncoding RNA LEF1-AS1 binds with HNRNPL to boost the proliferation, migration, and invasion in osteosarcoma by enhancing the mRNA stability of LEF1.2020Journal of cellular biochemistry
  2. miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo.2019FEBS letters
  3. MicroRNA-134 inhibits osteosarcoma angiogenesis and proliferation by targeting the VEGFA/VEGFR1 pathway.2018The FEBS journal

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 222025

4 hospitals in Taiyuan for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplantDrug combinations
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led6
  1. SYK identified by bioinformatics analysis promotes the proliferation of multiple myeloma.2025Expert review of hematology
  2. RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma.2025World journal of surgical oncologyFree full text
  3. Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.2024Annals of hematology
  4. The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.2024Cancer medicineFree full text
  5. MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma.2024Leukemia & lymphoma
  6. High expression of HOXC6 predicts a poor prognosis and induces proliferation and inflammation in multiple myeloma cells.2023Genes & genomics
Chinese-language papers (not in the count)15
  1. [COX6C Promotes the Proliferation of Multiple Myeloma Cells by Increasing Intracellular ATP Levels].2025Zhongguo shi yan xue ye xue za zhi
  2. [Prognostic Value of Prothrombin Time and Activated Partial Thromboplastin Time in Newly Diagnosed Patients with Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  3. [Mechanism and Clinical Significance of NAMPT in Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  4. [Expression and Clinical Significance of NAMPT in Bone Marrow of Patients with Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  5. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  6. [Risk Factors of Multiple Myeloma Complicated with Venous Thromboembolism].2023Zhongguo shi yan xue ye xue za zhi
  7. [Expression of NAMPT in Patients with Multiple Myeloma and Its Correlation with Clinical Manifestation].2023Zhongguo shi yan xue ye xue za zhi
  8. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].2023Zhongguo shi yan xue ye xue za zhi
  9. [The Value of Serum HMGB1 and sRAGE in the Diagnosis, Efficacy Monitoring and Prognosis of Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  10. [Evaluation of the Efficacy and Safety of Chemotherapy in Elderly Patients with Multiple Myeloma under Different Frailty Scores].2022Zhongguo shi yan xue ye xue za zhi
  11. [Clinical Characteristics and Prognosis of Multiple Myeloma Patients with Myelofibrosis].2022Zhongguo shi yan xue ye xue za zhi
  12. [Early Diagnosis of One Multiple Myeloma Patient with Cold Agglutinin Syndrome as the Initial Presentation].2021Zhongguo shi yan xue ye xue za zhi
  13. [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  14. [Clinical Characteristic, Prognosis and Treatment Outcome of Elderly Multiple Myeloma Patients with Impaired Renal Function].2021Zhongguo shi yan xue ye xue za zhi
  15. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  3. A Pilot Bioequivalence Study of PomalidomideCompletedNCT03424928Study sitePhase 1Start 2018-01
  4. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

1 hospital in Taiyuan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics & inherited formsLymphoma & cancer-related HLHDiagnosis & prognosis

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 6 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 2.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 2220242025: 002025

4 hospitals in Taiyuan for haemophilia A132 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT07644832

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led6
  1. Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro.2024Gene
  2. Diagnostic Value of the HEAD-US-C Scale for the Knees of Severe Hemophilia A Patients.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  3. The Correlation Between the HEAD-US-C Score and HJHS in Hemophilic Arthropathy of the Knee.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  4. Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B.2023Molecular genetics & genomic medicine
  5. Generation of iPSC line from urine cells of hemophilia A with F8 (p. R814X) mutation.2022Stem cell research
  6. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.2022Stem cell research & therapy
Chinese-language papers (not in the count)3
  1. [Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review].2023Zhongguo shi yan xue ye xue za zhi
  2. [Correlation Analysis of FⅧGene Mutation and the Production of FⅧ Inhibitor with Severe Hemophilia A Patients in a Single Medical Center].2022Zhongguo shi yan xue ye xue za zhi
  3. [Progress of Non-Factor Products in Hemophilia Treatment--Review].2022Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)2
  1. Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.2018Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  2. Musculoskeletal ultrasonography for arthropathy assessment in patients with hemophilia: A single-center cross-sectional study from Shanxi Province, China.2018Medicine
All its trials on ClinicalTrials.gov, any status8
  1. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Study sitePhase 1/Phase 2Start 2024-05
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  5. A Phase I of SS109 in Hemophilia A or and B With InhibitorsCompletedNCT05651061Study sitePhase 1Start 2022-12
  6. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  7. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  8. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia AStatus unknownNCT02930317Study sitePhase 3Start 2016-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Taiyuan for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Taiyuan for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologyENT / head & neck surgery
Papers it led4
  1. Clinical Performance of Immunonephelometric Assay and Chemiluminescent Immunoassay for Detection of IgG Subclasses in Chinese.2024Journal of clinical laboratory analysisFree full text
  2. Clinical Characteristics and CD4+ T Cell Subsets in IgG4-Related Disease.2022Frontiers in immunologyFree full text
  3. Response to "IgG4-Related Midline Destructive Disease" by Akiyama M.2021Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  4. Immunoglobulin G4-Related Disease Involving the Nasal Septum and Trachea.2021Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
More papers found outside PubMed (not counted)1
  1. AB0762 THE CHARACTERISTICS OF PERIPHERAL LYMPHOCYTE SUBSETS IN PATIENTS WITH IGG4-RELATED DISEASE2021Annals of the Rheumatic Diseasesconference-abstract

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Taiyuan for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

5 hospitals in Taiyuan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Taiyuan for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

2 hospitals in Taiyuan for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Taiyuan for Behçet disease139 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led1
  1. Low-dose IL-2 effectively restored decreased regulatory T cells in patients with Behçet's disease.2021Clinical and experimental rheumatology
Earlier papers (2016–2020)1
  1. [Clinical characteristics analysis of 1 808 rheumatism in-patients with oral candidiasis].2019Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

5 hospitals in Taiyuan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine
Papers it led4
  1. Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial.2025BMJ open
  2. Management and Clinical Outcomes of Membranous Nephropathy, IgA Nephropathy, and Minimal Change Disease Two Years Post-Kidney Biopsy.2024Kidney & blood pressure research
  3. Causal relationship between Helicobacter pylori infection and IgA nephropathy: a bidirectional two-sample mendelian randomization study.2024Renal failure
  4. Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis.2023Biomolecules & biomedicine
Chinese-language papers (not in the count)1
  1. [Renal leukocyte chemokine type 2 amyloidosis: a clinicopathological analysis of fifteen cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)2
  1. Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.2020International immunopharmacology
  2. Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study.2017American journal of kidney diseases : the official journal of the National Kidney Foundation
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taiyuan for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taiyuan for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山西医科大学第二医院

Second Hospital of Shanxi Medical University

太原

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
West Hospital of the Second Hospital of Shanxi Medical University; Second hospital of Shanxi Medical University; Shanxi Medical University Second Clinical Medical College; Shanxi Red Cross Hospital

Suggest a correctionDownload the data